Clough Capital Partners L P Acquires Shares of 13,789 GeneDx Holdings Corp. $WGS

Clough Capital Partners L P acquired a new stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,789 shares of the company’s stock, valued at approximately $1,793,000.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Arizona State Retirement System lifted its position in GeneDx by 2.1% during the fourth quarter. Arizona State Retirement System now owns 5,594 shares of the company’s stock valued at $728,000 after buying an additional 113 shares during the period. Cerity Partners LLC raised its position in shares of GeneDx by 6.0% in the 4th quarter. Cerity Partners LLC now owns 2,527 shares of the company’s stock worth $329,000 after purchasing an additional 142 shares during the last quarter. Main Management ETF Advisors LLC raised its position in shares of GeneDx by 1.0% in the 4th quarter. Main Management ETF Advisors LLC now owns 15,660 shares of the company’s stock worth $2,037,000 after purchasing an additional 160 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of GeneDx by 5.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,702 shares of the company’s stock worth $399,000 after purchasing an additional 181 shares during the last quarter. Finally, Jones Financial Companies Lllp raised its position in shares of GeneDx by 664.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares during the last quarter. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Trending Headlines about GeneDx

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Several law firms, including Rosen, Kahn Swick & Foti, Bernstein Liebhard, Bronstein Gewirtz & Grossman, Levi & Korsinsky, Pomerantz, Gross Law Firm and Schall, issued reminders or notices about the ongoing securities class action against GeneDx and the August 3 lead-plaintiff deadline. Article: WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
• Neutral Sentiment: One filing specifically alleges the stock’s decline was linked to alleged acquisition-performance misrepresentations and a large write-off related to the Fabric Genomics acquisition, keeping investor focus on past execution risks. Article: GeneDx Holdings (WGS) Faces Securities Class Action After 49% Drop, 94% Write-off Related to Fabric Genomics Acquisition
• Negative Sentiment: The lawsuits and repeated investor alerts may add legal overhang and could increase volatility in GeneDx shares as shareholders assess possible damages and reputational risk. Article: Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act

Analyst Ratings Changes

Several research firms have recently issued reports on WGS. Craig Hallum reaffirmed a “buy” rating and issued a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Wells Fargo & Company reaffirmed an “overweight” rating and issued a $75.00 price target (down from $155.00) on shares of GeneDx in a research report on Tuesday, May 5th. Weiss Ratings lowered GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. Wall Street Zen lowered GeneDx from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $130.00 price target (down from $160.00) on shares of GeneDx in a research report on Tuesday, February 24th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.43.

Insider Transactions at GeneDx

In other GeneDx news, Director Casdin Capital, Llc bought 185,000 shares of the firm’s stock in a transaction on Tuesday, May 19th. The stock was acquired at an average price of $42.60 per share, with a total value of $7,881,000.00. Following the transaction, the director owned 3,367,164 shares in the company, valued at $143,441,186.40. This represents a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Keith A. Meister bought 533,758 shares of the firm’s stock in a transaction on Thursday, May 7th. The stock was acquired at an average cost of $37.86 per share, with a total value of $20,208,077.88. Following the transaction, the director owned 3,761,908 shares in the company, valued at $142,425,836.88. The trade was a 16.53% increase in their position. The SEC filing for this purchase provides additional information. In the last three months, insiders acquired 2,256,420 shares of company stock valued at $93,144,340 and sold 54,402 shares valued at $3,395,647. 25.17% of the stock is currently owned by insiders.

GeneDx Price Performance

Shares of NASDAQ:WGS opened at $56.42 on Thursday. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The business has a 50-day simple moving average of $54.54 and a two-hundred day simple moving average of $87.44. The company has a debt-to-equity ratio of 0.38, a quick ratio of 2.95 and a current ratio of 3.09. The firm has a market cap of $1.68 billion, a price-to-earnings ratio of -21.05 and a beta of 1.96.

GeneDx (NASDAQ:WGS) last issued its earnings results on Monday, May 4th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). GeneDx had a positive return on equity of 9.15% and a negative net margin of 17.58%.The business had revenue of $102.25 million during the quarter, compared to analysts’ expectations of $112.46 million. During the same period last year, the firm posted ($0.23) EPS. On average, analysts expect that GeneDx Holdings Corp. will post -1 earnings per share for the current year.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.